New funding was received by Dr. Jeremy Johnson and Dr. Natalie Reizine to perform a phase I window of opportunity clinical in prostate cancer patients.
This funding is being supported by the University of Illinois Cancer Center and will be the first in human clinical trial evaluating glycyrrhizin in prostate cancer patients.
Glycyrrhizin is a triterpenoid isolated from licorice and has a long history of use in traditional medicine.
Glycyrrhizin is the sweet-tasting component of licorice (Glycyrrhiza glabra) root.
Some estimates suggest that 50 to 80% of Traditional Chinese Medicine contains licorice.
In addition, this ingredient has been historically used throughout European countries and can be traced to the ancient Greeks.
